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Summary
Background Skin and mucosal herpes simplex virus type 2 (HSV-2) shedding predominantly occurs in short subclinical 
episodes. We assessed whether standard-dose or high-dose antiviral therapy reduces the frequency of such shedding.
Methods HSV-2-seropositive, HIV-seronegative people were enrolled at the University of Washington Virology 
Research Clinic (WA, USA). We did three separate but complementary open-label cross-over studies comparing no 
medication with aciclovir 400 mg twice daily (standard-dose aciclovir), valaciclovir 500 mg daily (standard-dose 
valaciclovir) with aciclovir 800 mg three times daily (high-dose aciclovir), and standard-dose valaciclovir with 
valaciclovir 1 g three times daily (high-dose valaciclovir). The allocation sequence was generated by a random number 
generator. Study drugs were supplied in identical, numbered, sealed boxes. Study periods lasted 4–7 weeks, separated 
by 1 week wash-out. Participants collected genital swabs four times daily for quantitative HSV DNA PCR. Clinical 
data were masked from laboratory personnel. The primary endpoint was within-person comparison of shedding rate 
in each study group. Analysis was per protocol. The trials are registered at ClinicalTrials.gov (NCT00362297, 
NCT00723229, NCT01346475).
Results Of 113 participants randomised, 90 were eligible for analysis of the primary endpoint. Participants collected 
23 605 swabs; 1272 (5·4%) were HSV-positive. The frequency of HSV shedding was signiﬁ cantly higher in the no 
medication group (n=384, 18·1% of swabs) than in the standard-dose aciclovir group (25, 1·2%; incidence rate ratio 
[IRR] 0·05, 95% CI 0·03–0·08). High-dose aciclovir was associated with less shedding than standard-dose valaciclovir 
(198 [4·2%] vs 209 [4·5%]; IRR 0·79, 95% CI 0·63–1·00). Shedding was less frequent in the high-dose valaciclovir 
group than in the standard-dose valaciclovir group (164 [3·3%] vs 292 [5·8%]; 0·54, 0·44–0·66). The number of 
episodes per person-year did not diﬀ er signiﬁ cantly for standard-dose valaciclovir (22·6) versus high-dose aciclovir 
(20·2; p=0·54), and standard-dose valaciclovir (14·9) versus high-dose valaciclovir (16·5; p=0·34), but did for no 
medication (28·7) and standard-dose aciclovir (10·0; p=0·001). Median episode duration was longer for no medication 
than for standard-dose aciclovir (13 h vs 7 h; p=0·01) and for standard-dose valaciclovir than for high-dose valaciclovir 
(10 h vs 7 h; p=0·03), but did not diﬀ er signiﬁ cantly between standard-dose valaciclovir and high-dose aciclovir (8 h vs 
8 h; p=0·23). Likewise, maximum log10 copies of HSV detected per mL was higher for no medication than for standard-
dose aciclovir (3·3 vs 2·9; p=0·02), and for standard-dose valaciclovir than for high-dose valaciclovir (2·5 vs 3·0; 
p=0·001), but no signiﬁ cant diﬀ erence was recorded for standard-dose valaciclovir versus high-dose aciclovir (2·7 vs 
2·8; p=0·66). 80% of episodes were subclinical in all study groups. Except for a higher frequency of headaches with 
high-dose valaciclovir (n=13, 30%) than with other regimens, all regimens were well tolerated.
Interpretation Short bursts of subclinical genital HSV reactivation are frequent, even during high-dose antiherpes 
therapy, and probably account for continued transmission of HSV during suppressive antiviral therapy. More potent 
antiviral therapy is needed to eliminate HSV transmission.
Funding NIH. Valaciclovir was provided for trial 3 for free by GlaxoSmithKline. 
Introduction
Infection with herpes simplex virus type 2 (HSV-2) is 
a global epidemic,1 and signiﬁ cantly increases the risk 
of HIV-1 acquisition.2 Despite the increased use of 
antiviral therapy in the past two decades, the prevalence 
of, and complications from, HSV-2 infection have 
changed little.3,4 Daily antiviral therapy reduces genital 
lesions5,6 and suppresses detection of HSV on genital 
mucosal surfaces (shedding).7,8 However, treatment with 
daily valaciclovir results in only a 48% reduction in the 
risk of sexual transmission.9 Moreover, aciclovir does not 
eﬀ ectively reduce the risk of HIV transmission or 
acquisition in HSV-2-seropositive people.10–12 The dis-
crepancy between potent suppression of clinical 
symptoms and failure of antiviral agents to fully prevent 
HSV transmission is not well understood.
Intensive genital secretion collection shows that HSV 
shedding episodes are three-times more frequent than 
was previously realised.13 Nearly 50% of reactivations last 
less than 12 h; presumably they are cleared by the mucosal 
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immune system.13,14 Mathematical models suggest that 
these short bursts of shedding are even more frequent 
than current sampling methods can detect, constituting 
70–85% of all reactivations.15 Local host immune responses 
seem to control the severity, duration, and amount of 
virus detected during an outbreak.16 Trials using once 
daily genital sampling suggest that antiviral drugs reduce 
long episodes of high-copy-number HSV reactivation.7 
However, whether antiviral drugs suppress short 
reactivation events is unknown. Failure to do so could 
account for the lower than expected eﬀ ectiveness of 
antiviral drugs in clinical studies of HSV-2 transmission.
We did three complementary clinical studies to assess 
whether either standard or high doses of aciclovir and 
valaciclovir aﬀ ect the frequency of short, subclinical 
periods of HSV genital reactivation.
Methods
Patients
HSV-2-seropositive, HIV-seronegative healthy adults, 
aged 18 years or older were recruited at the University 
of Washington Virology Research Clinic between 
November, 2006, and July, 2010. In trial 1, patients with 
both symptomatic and asymptomatic genital herpes were 
recruited. In trials 2 and 3, participants needed to have 
had at least four clinical HSV-2 recurrences in the 
previous year or laboratory-documented primary genital 
HSV-2 in the previous 6 months. Participants with 
previous adverse reactions to aciclovir, pregnant women, 
and those unable to comply with study procedures were 
excluded. Participants were recruited through newspaper 
adver tisements, ﬂ iers, and by word of mouth. The studies 
were approved by the University of Washington Human 
Subjects Division and all participants provided written, 
informed consent.
Randomisation and masking
The random treatment allocation sequence was 
generated by a study statistician (MS) with a computerised 
random number generator. The sequence was known 
only to the statistician and the pharmacist, who prepared 
sequentially numbered, identical, sealed boxes con-
taining the study drug and the assignment of ﬁ rst group 
in the crossover. Participants were assigned the next 
sequential sealed box by a study clinician at enrolment. 
Random isation was stratiﬁ ed by sex. Patients were 
randomly assigned at a ratio of 1:1 for all drug groups. 
All three trials were open label, but clinical data were 
masked from laboratory personnel.
Procedures
Participants received the study medication for a 
prespeciﬁ ed period, had a 1 week wash-out period, and 
then crossed over to the other study medication for the 
remaining study period (ﬁ gure 1). Trial 1 was designed to 
test whether standard-dose aciclovir (400 mg twice daily) 
suppressed short subclinical episodes of HSV shedding 
compared with no medication. Each study period was for 
4 weeks. Trials 2 and 3 assessed whether higher doses 
of antiviral drugs or changes in the dosing schedule could 
provide more potent suppression of short shed-
ding episodes. Participants in trial 2—standard-dose 
valaciclovir (500 mg daily) versus high-dose aciclovir 
(800 mg three times daily)—were followed up for 7 weeks 
in each group. Participants in trial 3—standard-dose 
versus high-dose valaciclovir (1 g three times daily) were 
followed up for 5 weeks in each group. The high doses 
were selected to provide a two-to-three times (for high-
dose aciclovir)6,17 and an eight times (for high-dose 
valaciclovir)17 increase in the mean daily plasma aciclovir 
area under the curve (AUC) concentration, relative to 
46 patients screened
Trial 1
32 randomised
16 assigned no medication
for 4 weeks
16 assigned standard-dose
aciclovir for 4 weeks
3 lost to follow-up 6 lost to follow-up
1 week wash-out 1 week wash-out
13 assigned no medication
for 4 weeks
10 assigned standard-dose
aciclovir for 4 weeks
8 excluded
6 refused
48 patients screened
Trial 2
31 randomised
16 assigned standard-dose
valaciclovir for 7 weeks
15 assigned high-dose
aciclovir for 7 weeks
4 lost to follow-up
1 week wash-out 1 week wash-out
11 assigned standard-dose
valaciclovir for 7 weeks
16 assigned high-dose
aciclovir for 7 weeks
6 excluded
11 refused
63 patients screened
Trial 3
50 randomised
22 assigned standard-dose
valaciclovir for 5 weeks
28 assigned high-dose
valaciclovir for 5 weeks
3 lost to follow-up 4 lost to follow-up
1 week wash-out 1 week wash-out
25 assigned standard-dose
valaciclovir for 5 weeks
18 assigned high-dose
valaciclovir for 5 weeks
5 excluded
8 refused
Figure 1: Trial proﬁ les
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standard-dose valaciclovir. The high-dose valaciclovir 
dose, which is also used for treatment of herpes zoster,17 
was selected because clinical data suggest that this dose is 
safe. The study period was longer in trials 2 and 3 because 
we expected shedding rates during antiviral therapy to be 
low and we needed suﬃ  cient power to detect small 
diﬀ erences in shedding rates between the two groups.18
Participants self-collected one genital swab four times 
daily, about every 4–6 h while awake, during each study 
period.13 Women swabbed the vaginal vault, the entire 
labia majora and labia minora, the perineum, and 
perianal area. Men swabbed the penile shaft, scrotum, 
perineum, and perianal area. Participants recorded 
genital symptoms and lesions daily.19 Participants met a 
clinician once every 2 weeks for swab collection, 
medication administration, assessment of side-eﬀ ects, 
and genital examination, if symptomatic.
HSV serostatus was tested by western blot.20 Genital 
swabs were placed in 1 mL 1X PCR buﬀ er and stored at 
4°C. DNA was extracted from genital swabs, and HSV 
was quantiﬁ ed by real-time PCR, with HSV-speciﬁ c pri-
mers to glycoprotein B.21 Samples containing 150 copies 
of HSV DNA or more per mL of PCR buﬀ er were classed 
as positive.22
The primary outcome was HSV shedding rate, 
measured by the number of swabs with HSV detected 
divided by the number of swabs collected during each 
treatment period per participant, for each study. Secondary 
outcomes by treatment group were number of HSV 
shedding episodes, duration of HSV shedding episodes, 
and maximum quantity of HSV DNA detected in a 
shedding episode. Episodes were deﬁ ned as any number 
of swabs with HSV detected, immediately preceded by 
two negative swabs and followed by two negative swabs. 
Episode duration was extrapolated by estimation of start 
and stop times at the midpoint between the last HSV-
positive and ﬁ rst HSV-negative swabs. Participants who 
did not collect at least one swab during each study period 
were excluded from the analyses.
Adverse events were assessed at each study visit. White 
blood cell count, and renal and liver function tests were 
done once every 2 weeks in people enrolled in trial 3. 
Adverse events were graded with National Cancer 
Institute common terminology criteria (version 3.0).23
Statistical analysis
Estimates of shedding frequency were based on natural 
history studies using four samples per day,13,14 and within-
person correlation was estimated to be 0·2.7 Use of a 
sample size calculation for repeated-measures binary 
data24 and assumption of a genital shedding rate of 10% 
with no medication provides trial 1 with 80% power to 
detect a 35% reduction in genital shedding rates for 
standard-dose aciclovir. Assumption of a genital shedding 
rate of 3% for standard-dose valaciclovir7 provides trials 2 
and 3 with 80% power to detect a 50% reduction in HSV 
genital shedding rates for high-dose aciclovir or valaciclovir 
compared with standard-dose valaciclovir. A 20% loss to 
follow-up was assumed for all trials. The ﬁ rst day in each 
treatment period was excluded from the analysis. HSV 
genital shedding rates and episode rates were compared 
by Poisson regression, including a scale parameter for 
overdispersion and the log number of swabs as the oﬀ set. 
Sequence and period eﬀ ects were included in the model. 
Generalised estimating equations were used to compare 
shedding rates between no medication and drug groups 
in trials 2 and 3. Linear mixed models were used to 
compare episode rate, episode duration, maximum HSV 
log10 copy number during episodes, and HSV log10 copy 
number in positive swabs by treatment group, and to test 
for an association between episode duration and maximum 
HSV log10 copy number. Episode kinetics were calculated 
by computation of the slope of a linear regression line 
from the beginning to peak (expansion) or peak to end 
(clearance) of an episode.25 The Wilcoxon signed rank test 
for matched pairs was used to compare drug adherence 
rates by treatment as measured by pill counts. Correlation 
between adherence and genital shedding rate was 
measured with the Spearman correlation coeﬃ  cient. The 
yearly episode rate was calculated by dividing the number 
of episodes by the person-years of follow-up per treatment 
group. Two-sided p values less than 0·05 were judged 
statis tically signiﬁ cant. Data were analysed with Stata 
version 10.1. The trials are registered at ClinicalTrials.gov 
(NCT00362297, NCT00723229, NCT01346475).
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication. 
Results
Of 157 participants screened, 90 were enrolled and took 
samples for both study periods (ﬁ gure 1); three partici-
pants enrolled in both trial 1 and trial 3, so were excluded 
from the comparison of shedding rates between the no 
medication and drug groups. The median age was 
43 years (IQR 30–51). 49 (54%) participants were women, 
and 76 (84%) were white. 50 (56%) participants were 
HSV-2 seropositive only; 39 (43%) were HSV-1 and HSV-
2 seropositive. The median duration of HSV-2 infection 
was 7·6 years (IQR 1·8–19·5). The demo graphics of the 
study population were similar in each of the trials 
(webappendix).
90 participants took 23 605 (86%) of a possible 
27 319 swabs. Swabs were taken a median of 5·8 h 
(IQR 4·5–7·2) apart. 23 participants took 2123 swabs 
while receiving no medication, and HSV was detected in 
384 (18%) of these swabs (table, ﬁ gure 2). Although all 
doses of aciclovir reduced the frequency of detection of 
HSV compared with no medication (no medication vs 
standard-dose valaciclovir, p=0·003; no medication vs 
See Online for webappendix
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high-dose aciclovir, p=0·002; no medication vs high-dose 
valaciclovir, p<0·0001), breakthrough reactivation occur-
red at all drug doses (ﬁ gure 2). Fewer swabs had detectable 
HSV during standard-dose aciclovir compared with no 
medication (IRR 0·05, 95% CI 0·03–0·08). HSV 
detection was lower for high-dose aciclovir compared 
with standard-dose valaciclovir (table; IRR 0·79, 95% CI 
0·63–1·00). A dose eﬀ ect on HSV shedding was noted 
during high-dose valaciclovir compared with standard-
dose valaciclovir (table; IRR 0·54, 95% CI 0·44–0·66). No 
sequence eﬀ ects were detected for any trial (webappendix). 
Period eﬀ ects were present in all three trials and the 
models were adjusted accordingly.
In total, 344 genital HSV shedding episodes occurred 
(webappendix). The table shows characteristics of HSV 
shedding episodes by treatment group. Most shedding 
episodes were subclinical during all active treatment 
periods. Episodes were signiﬁ cantly less frequent in 
patients receiving standard-dose aciclovir than in those 
receiving no medication (p=0·001). Episode frequency 
did not diﬀ er between standard-dose valaciclovir and 
high-dose aciclovir (p=0·54), or between standard-dose 
and high-dose valaciclovir (p=0·34).
The median maximum number of HSV copies 
detected per episode was signiﬁ cantly higher during 
no medication than with standard-dose aciclovir (table; 
p=0·02). The quantity of HSV detected did not diﬀ er 
during episodes for standard-dose valaciclovir and high-
dose aciclovir (p=0·66), but it was signiﬁ cantly lower for 
high-dose valaciclovir than for standard-dose valaciclovir 
(p=0·001). The distribution of quantity of HSV detected 
on each antiviral dose is shown in the webappendix.
Of the 344 HSV shedding episodes, 84 were of unknown 
duration; in 44 (13%) cases the episode was detected at the 
No medication
Trial 1
IRR 0·05
95% CI 0·03–0·08
p<0·001
Trial 2
IRR 0·79
95% CI 0·63–1·00
p=0·052
Trial 3
IRR 0·54
95% CI 0·44–0·66
p<0·001
Estimated
aciclovir AUC 0 7·7 10 25 10 88
0
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Standard-dose
aciclovir
Standard-dose
valaciclovir
High-dose
aciclovir
Standard-dose
valaciclovir
High-dose
valaciclovir
35
40
45
50
Trial 1 Trial 2 Trial 3
No medication 
(N=23)
Standard-dose 
aciclovir (N=23)
Standard-dose 
valaciclovir (N=27)
High-dose 
aciclovir (N=27)
Standard-dose 
valaciclovir (N=43)
High-dose 
valaciclovir (N=43)
Genital HSV shedding rates
Overall
Swabs with HSV detected 384/2123 (18%) 25/2129 (1%) 209/4663 (4%) 198/4709 (4%) 292/5008 (6%) 164/4973 (3%)
Days with HSV detected 143/599 (24%) 21/604 (3%) 113/1251 (9%) 110/1274 (9%) 120/1378 (9%) 94/1395 (7%)
Per participant*
Swabs collected 96 (88–107) 96 (85–106) 180 (155–189) 178 (168–193) 121 (110–130) 117 (105–131)
Days in study 27 (26–28) 28 (26–29) 48 (48–49) 49 (48–50) 34 (34–35) 34 (34–35)
Swabs with HSV detected (%) 11 (0–32) 0 (0–1) 2 (1–4) 1 (0–3) 3 (0–9) 1 (0–4)
Days with HSV detected (%) 21 (0–38) 0 (0–4) 4 (2–13) 2 (0–6) 5 (0–15) 3 (0–10)
Characteristics of genital HSV shedding episodes
Episodes (n) 49 17 81 74 58 65
Episodes per person 1 (0–4) 0 (0–1) 2 (1–5) 1 (0–3) 1 (0–2) 1 (0–2)
Follow-up (person-years) 1·71 1·70 3·59 3·66 3·89 3·93
Subclinical episodes 32 (65) 16 (94) 74 (91) 68 (92) 37 (64)† 48 (74)‡
Annualised episode rate 
(episodes per person-year)
28·7 10·0 22·6 20·2 14·9 16·5
Episodes of known duration (n) 36 15 69 57 42 41
Episode duration (h) 13 (7–73) 7 (6–13) 8 (6–18) 8 (6–19) 10 (7–42) 7 (6–9)
Maximum log10 copies per mL 3·3 (2·5–5·7) 2·9 (2·4–3·4) 2·7 (2·4–3·1) 2·8 (2·5–3·2) 3·0 (2·4–4·5) 2·5 (2·3–2·7)
Data are n/N (%), n (%), or median (IQR) unless otherwise stated. HSV=herpes simplex virus. *The number of participants is as noted in ﬁ gure 1, excluding those who were 
lost to follow-up. †Data missing for three episodes. ‡Data missing for 11 episodes.
Table: HSV shedding outcomes
Figure 2: HSV detection in genital swabs 
Error bars are the 95% CIs. AUCs taken from Reitano and colleagues6 and Beutner and colleagues.17 IRR=incidence 
risk ratio. AUC=area under the curve (μg × h per mL). 
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beginning or end of the treatment period, and in 
40 (12%) swabs were missing. Of the 260 HSV shedding 
episodes of known duration, median episode duration 
was longer with no medication than for standard-dose 
aciclovir (table; p=0·01). The median episode duration 
was the same for standard-dose valaciclovir and high-dose 
aciclovir (p=0·23), but it was signiﬁ cantly shorter for high-
dose than for standard-dose valaciclovir (p=0·03). The 
median viral expansion in 6 h was much the same for 
standard-dose valaciclovir (4·6 log, IQR 1·5–5·7), high-
dose aciclovir (4·8 log, 1·5–5·5) and high-dose valaciclovir 
(4·7 log, 4·4–5·2). However, viral clearance in 6 h was 
greater for high-dose valaciclovir (4·7 log, 4·4–5·2) than 
for standard-dose valaciclovir (4·4 log, 0·8–4·7, p=0·016). 
Most shedding episodes on antiviral therapy were short 
irrespective of dose: 75 (60%) of 126 episodes with 
standard-dose antiviral therapy, 33 (58%) of 57 with high-
dose aciclovir, and 32 (78%) of 41 with high-dose valaciclovir 
lasted less than 12 h (webappendix). Episode duration was 
correlated with maximum log10 copy number during the 
episode (0·15 log for each 6 h increase, p<0·0001).
Demographic characteristics and shedding rates of 
participants who were lost to follow-up and those who 
completed the study did not diﬀ er (webappendix). 78–96% 
of participants in each study reported more than 85% 
adherence to the study medication, with a median 
adherence of 98–100% for each study group. No correlation 
between drug adherence and shedding was detected (data 
not shown). 3748 swabs were missing for participants 
included in the ﬁ nal analysis, which corresponds to 
1630 intervals when at least one swab was not taken. Of 
these intervals, 1129 (69%) had a swab missing at one 
point, 410 (25%) were missing a swab at two to ﬁ ve 
consecutive points, and 91 (6%) were missing swabs from 
more than ﬁ ve consecutive timepoints. Each study group 
and trial had a similar proportion of missing swabs (11·4%, 
14·3%, and 14·8% for trial 1, 2, and 3, respectively).
During high-dose valaciclovir therapy, 13 (30%) of 
43 participants complained of headache on at least 1 day 
(compared with none for standard-dose valaciclovir). 
Nausea (n=3; 7%), and myalgias (n=2; 5%) were also 
reported during high-dose valaciclovir. Two (5%) 
participants developed grade 2 neutropenia with high-
dose and standard-dose valaciclovir. No additional 
abnormalities in complete blood count, liver function, or 
renal function, or adverse events related to study 
medication were noted. We sequenced the HSV 
thymidine kinase gene from a representative swab 
sample26 of one participant with high rates of shedding in 
both study periods in trial 2 (webappendix), and did not 
detect any mutation known to confer aciclovir resistance 
(Genbank accession number HM446467).27
Discussion
Although daily antiviral therapy nearly eliminated 
symptomatic recurrences and reduced the frequency of 
episodes of shedding with high copy number, short 
episodes of genital HSV shedding occur frequently with 
antiviral therapy, even for high-dose regimens that 
increase the aciclovir AUC eight times compared with 
standard suppressive doses of aciclovir or valaciclovir. 
These breakthrough episodes are typically subclinical, 
last several hours, and occur at much the same rate 
irrespective of antiviral dose, providing a likely explan-
ation for the inability of daily suppressive therapy to 
completely abrogate HSV-2 transmission.
Studies measuring the clinical eﬀ ectiveness of aciclovir 
and valaciclovir in immunocompetent people have shown 
similar eﬃ  cacy, except in people with very frequent 
recurrences (panel).6 Initial clinical trials of aciclovir and 
valaciclovir showed high eﬃ  cacy for the prevention of 
genital herpes symptomatic recurrences.5,6 Trials that 
assessed suppression of subclinical shedding also showed 
a substantial eﬀ ect, although eﬃ  cacy was greater when 
measured by viral culture (roughly 95%)8 than by PCR 
(70–80%).7 Because of the high success in reduction of 
clinical and subclinical shedding, valaciclovir 500 mg daily 
was selected as the dose to test for reduction in sexual 
transmission of HSV. Interestingly, this dose reduced the 
sexual transmission of HSV by only 48% in discordant 
couples, despite a 73% reduction in subclinical shedding 
in the same population.9 In our study, most participants 
had one or two shedding episodes per month with both 
standard-dose and high-dose antiviral therapy. Despite the 
Panel: Research in context
Systematic review
A meta-analysis28 of 14 randomised clinical trials of antiviral 
therapy for herpes simplex virus type 2 (HSV-2) showed a 
47% (95% CI 45–49) overall relative risk reduction of 
recurrence in patients receiving suppressive therapy 
compared with placebo.28 Aciclovir and valaciclovir also 
suppress genital herpes shedding by 70–80% compared with 
placebo.7 Suppression of genital herpes with aciclovir and 
valaciclovir has been studied for public health beneﬁ t; to 
prevent both HSV-2 transmission,9 and HIV transmission12 
and acquisition.10,11 Despite a 70% reduction in genital HSV-2 
shedding, HSV-2 transmission was suppressed by only 48%.9 
Furthermore, HSV-2 suppression was not eﬀ ective in 
preventing HIV transmission12 or acquisition.10,11 These results 
have led to questions about the discrepancy between 
shedding rates and clinical outcomes, and whether increased 
doses of antiviral agents would be eﬀ ective.
Interpretation
Our results show that short episodes of subclinical shedding 
persist with both standard-dose and high-dose aciclovir and 
valaciclovir. Although HSV shedding was reduced by 50% with 
the highest doses of valaciclovir (1 g, three times daily), the rate 
of breakthrough shedding episodes did not change—about 
16–20 episodes per year. These data suggest that novel 
therapies are needed to completely prevent HSV reactivation.
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valaciclovir, to better detect a diﬀ erence in shedding rates 
between the study periods. Despite the attempt to show 
such a diﬀ erence, even very high doses of valaciclovir 
were associated with breakthrough genital HSV shedding. 
The trials were done at a single site, and enrolled 
mostly white, healthy, sexually active adults.33 The 
generalisability of these data to other geographic regions 
or racial or ethnic groups is unknown. Furthermore, we 
cannot extrapolate these ﬁ ndings to immunosuppressed 
patients. Although the studies were open label, we do not 
expect that this introduced bias because the endpoint 
(HSV shedding) is not subjective and laboratory personnel 
were masked to study group.
Although currently available anti-HSV therapy beneﬁ ts 
patients by preventing clinical HSV recurrences, 
suppressive therapies with greater potency, including 
antiviral drugs or immunotherapy in the form of 
therapeutic vaccines, are needed to provide substantial 
public health beneﬁ ts, such as prevention of HSV-2 
transmission and HIV-1 acquisition and transmission.
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